Clinical trial
SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation
NCT05935384 is registered in ClinicalTrials.gov with Guardant Health, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation
- Lead sponsor
- Guardant Health, Inc.
- Phase
- Observational
- Overall status
- Recruiting
- Start date
- October 25, 2023
- Completion date
- December 30, 2030
- Enrollment
- 470 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
breast cancer, colorectal cancer, non-small cell lung cancer